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Abstract 
Background. Prescribing of antidepressants varies widely between European 
countries despite no evidence of difference in the prevalence of affective disorders. 
Aims. To investigate associations between use of antidepressants, country-level 
spending on healthcare and attitudes towards mental health problems. 
Method. We used Eurobarometer 2010, a large general population survey from 27 
European countries, to measure antidepressant use and regularity of use. We 
analysed associations with country-level spending on healthcare and country-level 
attitudes towards mental health problems. 
Results. Higher country spending on healthcare was strongly associated with regular 
use of antidepressants. Beliefs that mentally ill people are ‘dangerous’ were 
associated with higher use, and beliefs that they ‘never recover’ or ‘have themselves 
to blame’ with lower use and less regular use of antidepressants.  
Conclusions. Contextual factors such as healthcare spending and public attitudes 
towards mental illness may partly explain variations in antidepressant use and 
regular use of these medications.  
Declaration of interest. None  
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Background 
Prescribing of antidepressants in Europe increased by an average of 20% per year 
between 2000 and 2010.1 However, the quantity of antidepressant prescribing varies 
widely between countries, with 6.4 times as many antidepressants prescribed per 
person in Iceland than Estonia in 2010.2 A large body of research into the 
epidemiology of depression and anxiety disorders shows higher prevalence among 
women, individuals in late middle age and those of lower socio-economic status,3,4 
but no substantial difference between European countries.5 Little is known about 
reasons for the inter-country variation in antidepressant use. Variations in treatment 
seeking, availability of providers, spending on healthcare services and other 
differences between healthcare systems are likely important factors. Social attitudes 
towards mental illness may also play a role, as is the case for help-seeking for 
mental health problems.6,7 In this study, we investigated individual and country level 
factors associated with: (i) any antidepressant use and (ii) regularity of 
antidepressant use among those who reported antidepressant use, as a quality 
indicator for treatment regimens. Regularity is important because clinical guidelines 
recommend that antidepressants be taken regularly for a minimum period of a few 
months,8 and adherence has been shown to be low in community settings.9 We 
hypothesized that antidepressant use patterns would reflect sociodemographic 
characteristics associated with affective disorders, and that higher levels of 
healthcare spending and lower levels of mental health related stigma in each country 
would be associated with higher levels of antidepressant use and greater regularity. 
Methods 
Data Source 
The key data source was Eurobarometer 2010. This is a cross-sectional survey of 
residents of 27 EU member states, with approximately 1,000 individuals from each 
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country interviewed. Participants were recruited via multistage random probability 
sampling and were representative of residents of each country aged 15 years or 
older. Data were collected via face-to-face interviews (n=26,800). Full details of the 
design and sampling are given elsewhere.10,11  
As this study was based on fully anonymised publicly available data, ethical approval 
was not needed. 
Dependent variables 
Two dichotomous dependent variables derived from Eurobarometer 2010 were 
examined:  
Any use of antidepressants in the past 12 months. Participants were asked: ‘Have 
you taken any antidepressants in the last 12 months?’ Responses were (1) ‘Yes, 
regularly for a period of at least 4 weeks’; (2) ‘Yes, regularly for a period of less than 
4 weeks’; (3) ‘Yes, from time to time when I felt the need’; and (4) ‘No, not at all.’ 
These responses were combined into ‘any use’ vs. ‘no use’. 
Regularity of use among antidepressant users. The first two responses from the 
above question were combined into an indicator variable for regular use vs. non-
regular use. 
Independent variables 
Individual-level variables were taken from Eurobarometer 2010. The sources of 
country-level variables were taken from various sources and these are described 
below. 
Socio-demographic information included age (grouped into 15-39, 40-54 and 55+ 
years), sex and employment status. To assess employment status, participants were 
asked, ‘what is your current occupation?’ Students and employed participants were 
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categorised as ‘employed’. Participants looking after the home, ill or retired were 
categorised as ‘economically inactive’ and the remainder were rated as unemployed. 
Self-perceived social class was assessed by asking the participants to place 
themselves on a ladder, step '1' of which corresponded to the lowest level in society 
and step '10' to the highest. Individuals placing themselves on levels 1-4 were 
categorised as ‘low’, 5-6 as ‘medium’ and 7-10 as ‘high’. 3.1% of individuals refused 
to answer this question. Data for these individuals were imputed from their 
occupation and whether they had difficulty paying bills. 
Mental health symptoms were assessed using the Mental Health Inventory (MHI-5). 
The MHI-5 is a valid and reliable measure of common mental disorders derived from 
the Short Form 36 (SF-36).12,13 Higher scores indicate worse mental health. As a 
validated cut-point has not been established for this scale,14 individuals were 
categorised into three groups: those with the worst mental health, scoring in the top 
5% on MHI-5; those with poorer than average mental health, scoring above the 
median score but excluding the top 5%; and those with better than average mental 
health, scoring lower than the median value. 1.3% of individuals answered ‘don’t 
know’ to some MHI-5 items. In these cases, the mean score from other items was 
used. 0.2% of individuals answered ‘don’t know’ to all MHI-5 items and their scores 
were imputed from their sex and occupation.  
Individual attitudes towards people with mental health problems. Attitudes of 
individual Eurobarometer 2010 participants were assessed by the question, ‘which of 
the following two statements best describe how you feel?’: (1) ‘you would find it 
difficult talking to someone with a significant mental health problem?’, (2) ‘you would 
have no problem talking to someone with a significant mental health problem?’, (3) 
‘don’t know’. Participants who gave options (2) and (3) were grouped together.  
Difficulty paying bills was used as an indicator of financial difficulties. Participants 
were asked: ‘during the last twelve months, would you say you had difficulties to pay 
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your bills at the end of the month’. The responses ‘from time to time’ and ‘most of the 
time’ were grouped as indicating difficulty, and ‘never’ and ‘refusal’ were grouped as 
no difficulty. 
Country-level health care spending. World Bank data provided annual health care 
spending per capita in US$ in 2010, which ranged from $457 in Romania to $8,193 in 
Luxembourg.15 The 27 European countries are distributed across this range, and 
were therefore assigned to four equally sized groups: those spending $457-$1,002, 
$1,402-$2,872, $2,895-$4,618 and $4,658-$8,193 per capita. 
Country prevalence of stigmatising attitudes towards people with mental health 
problems was assessed in Eurobarometer 2006 using four questions about various 
stigmatizing beliefs: people with psychological or emotional health problems: (1) 
constitute a danger to others; (2) are unpredictable; (3) have themselves to blame; 
and (4) never recover. Participants rated their agreement on a 4-point Likert scale 
from ‘totally disagree’ to ‘totally agree’. Those responding ‘totally agree’ or ‘tend to 
agree’ were grouped together as endorsing the statement. The country-level 
measures were computed as the proportion of respondents endorsing each 
statement in each country. Each country-level attitude variable was standardised and 
a z-score was computed as an indicator of how far away (in standard deviations) the 
country prevalence was from the mean prevalence. 
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Statistical analysis 
Separate multivariable logistic regression models were used to examine predictors of 
the two outcome variables—any use of antidepressants and regularity of use. The 
model for any use of antidepressants included the full sample (n=26,800), and the 
model for regular use was limited to those who reported any use (n=1,995). 
Eurobarometer 2010 post-stratification weights, based on sex, age, region and size 
of locality, were used in all analyses to estimate the country-level averages. All 
analyses were carried out using R version 3.0.3. 
Results  
Prevalence of antidepressant use 
7.2% (n=1,995) of adults reported taking antidepressants at some time in the past 
year. There was wide variation between countries in prevalence of antidepressant 
use, from 15.7% in Portugal to 2.7% in Greece (figure 1). Overall prevalence of 
antidepressant use by sociodemographic and mental health related characteristics 
are presented in table 1. 
Table 1 here 
Figure 1 here 
Characteristics associated with antidepressant use 
The multivariable regression results presented in Table 2 show that individuals had 
higher odds of taking antidepressants if they: had higher MHI-5 scores, were female, 
were aged over 40 years old, were not employed or looking after the home 
(compared to those employed or studying), perceived themselves to be of lower 
social class and reported difficulty paying bills. Comfort with talking to someone with 
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a mental health problem was not associated with the odds of taking antidepressants. 
Individuals had higher odds of taking antidepressants if they lived in a country that 
spent more on healthcare (but the relationship did not show a clear gradient and 
unadjusted odds ratios were not statistically significant – see online appendix), lived 
in a country where residents were more likely to consider people with mental illness 
to be dangerous, or a country where residents were less likely to consider people 
with mental illness to never recover or to have themselves to blame for their illness. 
Table 2 here 
Characteristics associated with regularity of antidepressant use 
58% of antidepressant users reported regular use of antidepressants. There was 
wide variation between countries, from 89% in Sweden to 19% in Bulgaria (figure 2). 
The multivariable regression results show that individuals who reported taking 
antidepressants had higher odds of taking them regularly if they had a higher MHI-5 
score, were more comfortable talking to someone with a mental health problem and 
were younger (table 2). There were no significant associations with sex, employment 
status, perceived social class or difficulty paying bills. At the country level, individuals 
had higher odds of taking antidepressants regularly if they resided in a country that 
spent more on health care per capita, where residents were more likely to consider 
people with mental illness to be unpredictable, and where residents were less likely 
to consider people with mental illness to never recover. At a country level, there was 
no statistically significant correlation between prevalence of antidepressant use and 
the proportion of antidepressant users reporting regular use (r = 0.15, p = 0.44). 
Figure 2 here 
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Discussion 
This study provides new insights into how societal attitudes and spending on 
healthcare are associated with antidepressant use. These findings explain some of 
the variation in antidepressant use across Europe and provide further evidence for 
the relationship between stigma and treatment for mental illness. The findings also 
contribute substantively to the study of the epidemiology of antidepressant use in 
Europe, which to date provides limited insight into the socio-demographic and 
contextual correlates of variations across countries.  
The 12-month prevalence of antidepressant use of 7.2% in 2010 is double a previous 
estimate of 3.7% in 2000,16 which reflects a doubling in prescription rates over the 
same period in 18 European countries.2 The demographic associations with 
antidepressant use in Europe have not been investigated in detail in previous 
research. One study in Europe17 showed that women and those in middle age are 
more likely to use antidepressants, which is consistent with our findings. Our findings 
are also broadly consistent with studies from the US, which show that older people, 
women and people with worse mental health are more likely to take 
antidepressants.18–20 
The socio-demographic characteristics associated with antidepressant use in this 
study were similar to those typically found to be associated with affective disorders in 
community surveys.3,5 At the country level, health spending and stigmatising attitudes 
were associated with antidepressant use to some extent. Interestingly, different 
aspects of stigma had opposite effects on likelihood of taking antidepressants. 
The prevalence of regular use of antidepressants is low in view of practice guideline 
recommendations that they should be taken regularly for effective treatment, with 
only 58% of the participants reporting that they take them regularly. This is also 
consistent with existing research, which shows low adherence to antidepressant 
regimens. An international review of studies showed a median adherence rate of only 
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40%.9 Low adherence may be due to prescriber factors. For example, in a study of 
prescribing between 1992 and 1997 in the UK,21 only 33% of SSRI prescriptions 
were consistent with guidelines. Patients’ concerns about dependence, toxicity and 
stigma may also contribute to the low rate of regular use.22 Finally, patients may 
discontinue antidepressants early because they start to feel better. 
The results regarding regularity of use within demographic groups are relevant to 
clinical practice. In particular, we found that middle-aged and older adults are less 
likely to take antidepressants regularly. Clinicians may thus want to pay greater 
attention to monitoring medication use in this age group. 
One of the most striking results from this study was the strong association of 
healthcare spending with regular use of antidepressants. A possible explanation is 
that physicians in better-funded health care systems have more time, training and 
support and make more accurate diagnoses and prescribe more effective drug 
regimens. Alternatively, better-funded health care systems may provide more 
guidance to patients on use of drugs or make drugs more affordable. A study in 
Australia found that an increase in co-payments (transferring some of the cost of 
drugs to patients) reduced dispensing.23 
We found no correlation at a country level between prevalence of antidepressant use 
and the proportion of antidepressant users reporting regular use. We might have 
expected countries with higher prevalence to have more people with less severe 
symptoms taking antidepressants, and therefore lower regularity of use. However, 
this did not appear to be the case. Regularity of use appears low in Eastern 
European countries and high in Scandinavian countries. As these countries tend to 
have lower and higher per capital income respectively, it is difficult to tease out the 
contribution of economic factors and regional cultural factors. We included proxies for 
both of these variables in our analyses and this suggests that economic and cultural 
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factors may independently contribute to the likelihood of individuals taking 
antidepressants regularly.  
The results relating to stigmatising attitudes are complex and merit some discussion. 
It is clear that individual and country level attitudes play an important role in whether 
and how people use antidepressants. At an individual level, comfort talking to 
someone with a mental health problem does not appear to make people more or less 
likely to use antidepressants, but does appear to make people less likely to use 
these medications regularly. 
As has been shown previously, different types of social stigma vary in their 
association with outcomes for people with mental illness.6 The findings from our 
study suggest that individuals living in a country where a higher proportion of the 
public believes that people with mental illnesses are ‘dangerous’ is associated with a 
greater likelihood of using antidepressants. Other research has shown that a belief 
that people with mental illnesses are dangerous is associated with greater likelihood 
of help-seeking,7 more support for coercive treatment24,25 and a biogenetic 
explanation for mental illness.26 It may be that a ‘medicalised’ concept of mental 
illness in which mental illness is considered ‘a disease like any other’,27 which can be 
treated with effective medical therapy, contributes to greater use of medical 
treatments such as antidepressants. Conversely, living in a country with stronger 
beliefs that people with mental illness ‘have themselves to blame’ or ‘never recover’ 
was associated with a lower likelihood of using antidepressants and lower regularity 
of use. The view that people with mental illnesses ‘never recover’ has particularly 
strong and significant inverse associations with antidepressant use and regular use. 
Viewing mental illness as a personality fault or an incurable illness may contribute to 
lower likelihood of use of medical therapies. Other research has also shown that 
attitudes regarding blame are associated with lower rates of willingness to seek help 
and are often inversely associated with endorsement of a biogenetic model. These 
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results support the idea that medicalised views of mental illness may act as a ‘double 
edged sword’, leading to higher rates of treatment but also greater social distance27–
29 and social exclusion, for example from employment.30 
Strengths and limitations 
This study was based on a large and representative sample and included both 
individual and contextual variables from 27 diverse European countries, providing 
powerful models. Nevertheless, the study had a number of limitations. First, 
Eurobarometer is a cross-sectional survey, thus limiting causal inference. Second, 
many of the variables used are based on self-report and may be vulnerable to recall 
bias. It was not possible to verify antidepressant use with medical records; however, 
past research has shown good agreement between self-reports of medication use 
and pharmacy records and low risk of bias.31,32 Third, mental health status was 
determined via a brief self-report measure and not verified by a clinician. 
Furthermore, specific mood and anxiety disorders could not be assessed based on 
these data. However, mean MHI-5 scores were highest for women and people aged 
40-54, which corresponds with patterns of common mental disorders and supports 
validity of the data. Additionally, some of the effect sizes are small and thus, we have 
tried to emphasise the magnitude of the association in addition to statistical 
significance given the relatively large sample size. Finally, the data are based on 
European countries only, which have specific health care systems and attitudes 
towards mental health and medications, and therefore the results may not be 
generalisable to other regions.  
Conclusions 
In the context of these limitations, these findings provide a broad view of both 
individual and sociocultural correlates of antidepressant use. Some of the wide 
variation in antidepressant use across Europe is explained by differences in 
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healthcare spending and attitudes towards mental illness. Healthcare spending in 
this study is likely a proxy for many variables, including availability of medical care, 
training of healthcare staff and affordability of drugs. Our study shows that healthcare 
spending is strongly associated with regularity of antidepressant use. In addition, 
attitudes towards people with mental illness are associated with both use and 
regularity of use. Policy aiming to achieve appropriate prescribing and use of 
antidepressants will need to consider individual and social attitudes as well as 
medical practices. Variations in the association of various attitudinal factors with 
antidepressant use points to the need for a more nuanced approach to messages 
incorporated in public mental health campaigns. The view that people with mental 
illness cannot recover or are blame-worthy for their illness appear to be strong 
barriers to appropriate and regular use of antidepressants. Countering these beliefs 
through public health campaigns and interventions may thus help to improve access 
to and more appropriate use of antidepressant medications.  
14 
 
References 
1  Gusmão R, Quintão S, McDaid D, Arensman E, Van Audenhove C, Coffey C, et 
al. Antidepressant Utilization and Suicide in Europe: An Ecological Multi-National 
Study. PLoS ONE 2013; 8: e66455. 
2  OECD. Health at a Glance: Europe 2012. OECD Publishing, 2012. 
3  McManus S, Bebbington P, National Centre for Social Research (Great Britain) U 
of L, Department of Health Sciences, Great Britain, National Health Service, et al. 
Adult psychiatric morbidity in England, 2007: results of a household survey. 
National Centre for Social Research, 2009. 
4  Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe—a 
critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 
357–76. 
5  Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. 
The size and burden of mental disorders and other disorders of the brain in 
Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655–79. 
6  Evans-Lacko S, Brohan E, Mojtabai R, Thornicroft G. Association between public 
views of mental illness and self-stigma among individuals with mental illness in 
14 European countries. Psychol Med 2012; 42: 1741–52. 
7  Mojtabai R. Mental illness stigma and willingness to seek mental health care in 
the European Union. Soc Psychiatry Psychiatr Epidemiol 2010; 45: 705–12. 
8  Anderson I, Ferrier I, Baldwin R, Cowen P, Howard L, Lewis G, et al. Evidence-
based guidelines for treating depressive disorders with antidepressants: A 
revision of the 2000 British Association for Psychopharmacology guidelines. J 
Psychopharmacol (Oxf) 2008; 22: 343–96. 
9  Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta 
Psychiatr Scand 2002; 105: 164–72. 
10  European Union. Mental Health: Special Eurobarometer 345/Wave 73.2. 2010. 
(http://ec.europa.eu/public_opinion/archives/ebs/ebs_345_en.pdf). 
11  European Union. Mental Wellbeing: Special Eurobarometer 248/Wave 64.4. 
2006. (http://ec.europa.eu/public_opinion/archives/ebs/ebs_248_en.pdf). 
12  McCabe C, Thomas K, Brazier J, Coleman P. Measuring the mental health status 
of a population: a comparison of the GHQ-12 and the SF-36 (MHI-5). Br J 
Psychiatry 1996; 169: 516–21. 
13  Ware Jr JE, Gandek B. Overview of the SF-36 health survey and the 
international quality of life assessment (IQOLA) project. J Clin Epidemiol 1998; 
51: 903–12. 
14  Kelly MJ, Dunstan FD, Lloyd K, Fone DL. Evaluating cutpoints for the MHI-5 and 
MCS using the GHQ-12: a comparison of five different methods. BMC Psychiatry 
2008; 8: 10. 
15 
 
15  World Bank. World Development Indicators 2012. 2012. 
(http://data.worldbank.org/sites/default/files/wdi-2012-ebook.pdf). 
16  Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. 
Psychotropic drug utilization in Europe: results from the European Study of the 
Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 
2004; 109: 55–64. 
17  Ohayon MM, Lader MH. The use of psychotropic medication in the general 
population of France, Germany, Italy and the United Kingdom. J Clin Psychol 
2002; 63: 817–25. 
18  Mojtabai R, Olfson M. National Trends in Long-Term Use of Antidepressant 
Medications: Results From the US National Health and Nutrition Examination 
Survey. J Clincial Psychiatry 2014; 75: 169–77. 
19  Pratt LA, Brody DJ, Gu Q, (US) NC for HS. Antidepressant use in persons aged 
12 and over: United States, 2005-2008. 2011. 
(http://www.cybermed.eu/attachments/article/33763/Antidepressant%20Use%20i
n%20Persons%20Aged%2012%20and%20Over%20United%20States,%202005
%C2%AD2008-1.pdf). 
20  Stagnitti M N. Antidepressant Use in the U.S. Civilian Noninstitutionalized 
Population, 2002. 2005. 
21  Dunn RL, Donoghue JM, Ozminkowski RJ, Stephenson D, Hylan TR. 
Longitudinal patterns of antidepressant prescribing in primary care in the UK: 
comparison with treatment guidelines. J Psychopharmacol (Oxf) 1999; 13: 136–
43. 
22  Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, et al. 
Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc 
Sci Med 2005; 61: 133–55. 
23  Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact 
of co-payment increases on dispensings of government-subsidised medicines in 
Australia. Pharmacoepidemiol Drug Saf 2008; 17: 1091–9. 
24  Corrigan P, Markowitz FE, Watson A, Rowan D, Kubiak MA. An Attribution Model 
of Public Discrimination Towards Persons with Mental Illness. J Health Soc 
Behav 2003; 44: 162. 
25  Mossakowski KN, Kaplan LM, Hill TD. Americans’ Attitudes toward Mental Illness 
and Involuntary Psychiatric Medication. Soc Ment Health 2011; 1: 200–16. 
26  Kvaale EP, Gottdiener WH, Haslam N. Biogenetic explanations and stigma: A 
meta-analytic review of associations among laypeople. Soc Sci Med 2013; 96: 
95–103. 
27  Pescosolido BA, Martin JK, Long JS, Medina TR, Phelan JC, Link BG. ‘A disease 
like any other’? A decade of change in public reactions to schizophrenia, 
depression, and alcohol dependence. Am J Psychiatry 2010; 167: 1321–30. 
16 
 
28  Rüsch N, Todd AR, Bodenhausen GV, Corrigan PW. Biogenetic models of 
psychopathology, implicit guilt, and mental illness stigma. Psychiatry Res 2010; 
179: 328–32. 
29  Schomerus G, Schwahn C, Holzinger A, Corrigan PW, Grabe HJ, Carta MG, et 
al. Evolution of public attitudes about mental illness: a systematic review and 
meta-analysis: Evolution of public attitudes. Acta Psychiatr Scand 2012; 125: 
440–52. 
30  Evans-Lacko S, Knapp M, McCrone P, Thornicroft G, Mojtabai R. The Mental 
Health Consequences of the Recession: Economic Hardship and Employment of 
People with Mental Health Problems in 27 European Countries. PLoS ONE 2013; 
8: e69792. 
31  Cotterchio M, Kreiger N, Darlington G, Steingart A. Comparison of self-reported 
and physician-reported antidepressant medication use. Ann Epidemiol 1999; 9: 
283–9. 
32  Kwon A, Bungay KM, Pei Y, Rogers WH, Wilson IB, Zhou Q, et al. 
Antidepressant use: concordance between self-report and claims records. Med 
Care 2003; 41: 368–74. 
 
 
  
17 
 
Table 1: Prevalence of antidepressant use and regular antidepressant use among 
those who use antidepressants, showing 95% confidence intervals  
 
  
Any use of 
antidepressants in the 
last 12 months 
(general population) 
Taking regularly 
(antidepressant users 
only) 
Percent Percent 
MHI-5 
5-10 2.0 (1.7-2.2) 60.5 (54.1-66.6) 
11-17 9.5 (9.0-10.0) 54.5 (51.6-57.3) 
18+ 34.6 (32.1-37.2) 66.8 (62.4-71.0) 
Comfortable talking to someone 
with a mental health problem 
Yes 6.9 (6.5-7.3) 63.3 (60.5-66.1) 
No 7.9 (7.3-8.4) 49.7 (46.0-53.4) 
Sex 
Female 9.4 (8.9-9.9) 58.2 (55.5-60.9) 
Male 4.9 (4.5-5.3) 58.1 (54.0-62.1) 
Age 
15-39 4.5 (4.1-5.0) 64.8 (60.2-69.3) 
40-54 8.6 (8.0-9.3) 60.8 (56.7-64.8) 
55+ 9.5 (8.9-10.1) 52.3 (49.1-55.6) 
Employment status 
Employed 4.5 (4.2-4.9) 61.0 (57.2-64.7) 
Economically inactive 11.0 (10.4-11.7) 55.6 (52.5-58.7) 
Unemployed 10.4 (9.2-11.7) 60.2 (53.6-66.5) 
Self-perceived social class 
Low 12.4 (11.6-13.3) 56.0 (52.2-59.7) 
Medium 6.5 (6.1-7.0) 58.7 (55.2-62.0) 
High 4.8 (4.3-5.3) 62.1 (56.9-67.2) 
Difficulty paying bills 
No 5.1 (4.8-5.5) 62.6 (59.2-65.8) 
Yes 10.6 (10.0-11.2) 54.7 (51.7-57.7) 
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Figure 1: Percentage of general population that have used antidepressants in the 
past 12 months by country, with 95% confidence intervals (note maximum value of 
15.7%) 
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Figure 2: Percentage of antidepressant users that report taking them regularly by 
country, with 95% confidence intervals 
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Table 2: Result of the multivariable logistic regression models for predictors of antidepressant use in Eurobarometer 2010. 
  
Any use of antidepressants in 
last 12 mths 
(Sample = 26,800; users = 1,995) 
AOR (95% CI) 
Taking regularly  
(Sample = 1,995; regular users = 
1,154) 
AOR (95% CI) 
Individual 
level 
variables 
MHI-5 (ref = 5-10)   
11-17 4.77 (4.11-5.52)*** 1.14 (0.83-1.57) 
18+ 19.43 (16.11-23.43)*** 2.51 (1.72-3.66)*** 
Uncomfortable talking to someone with a mental health problem 0.98 (0.88-1.09) 0.71 (0.58-0.88)*** 
Male sex 0.62 (0.55-0.69)*** 0.93 (0.75-1.16) 
Age (ref = 15-39)   
40-54 1.69 (1.47-1.94)*** 0.74 (0.56-0.99)* 
55+ 1.45 (1.24-1.71)*** 0.58 (0.42-0.78)*** 
Labour status (ref = employed)   
Economically inactive 1.76 (1.51-2.04)*** 1.10 (0.85-1.43) 
Unemployed 1.53 (1.28-1.83)*** 0.92 (0.65-1.30) 
Perceived SES (ref = low)   
Mid 0.75 (0.66-0.85)*** 0.88 (0.70-1.11) 
High 0.71 (0.60-0.84)*** 0.85 (0.62-1.16) 
Difficulty paying bills 1.44 (1.28-1.62)*** 0.84 (0.67-1.05) 
Country 
level 
variables 
Health spend pc (ref = <$1000)   
$1000 - $2999 1.58 (1.35-1.87)*** 1.48 (1.06-2.06)* 
$3000 - $4499 1.77 (1.47-2.13)*** 2.34 (1.62-3.37)*** 
$4500+ 1.79 (1.45-2.20)*** 4.75 (3.01-7.48)*** 
Stigmatising attitudes: z-score of % agreeing that mentally ill people:   
‘Are unpredictable’ 1.06 (0.97-1.15) 1.27 (1.06-1.53)* 
‘Are dangerous’ 1.27 (1.16-1.38)*** 1.15 (0.96-1.38) 
‘Never recover’ 0.87 (0.79-0.95)*** 0.56 (0.46-0.69)*** 
‘Have selves to blame’ 0.79 (0.71-0.87)*** 0.81 (0.66-1.01). 
AOR = Adjusted odds ratio; CI=confidence interval 
*** p <0.001, ** p <0.01, * p < 0.05, . p < 0.1 
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Online Appendix: Result of logistic regression models for predictors of antidepressant use in Eurobarometer 2010. 
  
General population (sample = 26,800) AD users (sample = 1,995) 
  
Any use of antidepressants in last 12 mths 
(users = 1,995) 
Taking regularly  
(regular users = 1,154) 
  UOR (95% CI) AOR (95% CI) UOR (95% CI) AOR (95% CI) 
Individual 
level 
variables 
MHI-5 (ref = 5-10)     
11-17 5.19 (4.50-5.99)*** 4.77 (4.11-5.52)*** 0.78 (0.59-1.04). 1.14 (0.83-1.57) 
18+ 26.31 (22.15-31.25)*** 19.43 (16.11-23.43)*** 1.31 (0.95-1.82) 2.51 (1.72-3.66)*** 
Uncomfortable talking to someone with a mental health problem 1.16 (1.05-1.28)*** 0.98 (0.88-1.09) 0.57 (0.47-0.69)*** 0.71 (0.58-0.88)*** 
Male sex 0.49 (0.44-0.55)*** 0.62 (0.55-0.69)*** 1.00 (0.82-1.22) 0.93 (0.75-1.16) 
Age (ref = 15-39)     
40-54 2.00 (1.75-2.28)*** 1.69 (1.47-1.94)*** 0.84 (0.65-1.09) 0.74 (0.56-0.99)* 
55+ 2.22 (1.97-2.50)*** 1.45 (1.24-1.71)*** 0.59 (0.47-0.75)*** 0.58 (0.42-0.78)*** 
Labour status (ref = employed)     
Economically inactive 2.60 (2.34-2.88)*** 1.76 (1.51-2.04)*** 0.80 (0.66-0.98)* 1.10 (0.85-1.43) 
Unemployed 2.44 (2.08-2.86)*** 1.53 (1.28-1.83)*** 0.97 (0.71-1.32) 0.92 (0.65-1.30) 
Perceived SES (ref = low)     
Mid 0.48 (0.43-0.54)*** 0.75 (0.66-0.85)*** 1.10 (0.90-1.35) 0.88 (0.70-1.11) 
High 0.35 (0.30-0.40)*** 0.71 (0.60-0.84)*** 1.29 (0.99-1.68). 0.85 (0.62-1.16) 
Difficulty paying bills 2.19 (1.99-2.41)*** 1.44 (1.28-1.62)*** 0.72 (0.60-0.87)*** 0.84 (0.67-1.05) 
Country 
level 
variables 
Health spend pc (ref = <$1000)     
$1000 - $2999 1.12 (0.98-1.27). 1.58 (1.35-1.87)*** 1.40 (1.09-1.81)* 1.48 (1.06-2.06)* 
$3000 - $4499 1.11 (0.98-1.26) 1.77 (1.47-2.13)*** 3.15 (2.44-4.07)*** 2.34 (1.62-3.37)*** 
$4500+ 0.88 (0.76-1.01). 1.79 (1.45-2.20)*** 4.05 (3.00-5.47)*** 4.75 (3.01-7.48)*** 
Stigmatising attitudes: z-score of % agreeing that mentally ill people:     
‘Are unpredictable’ 1.06 (1.02-1.11)* 1.06 (0.97-1.15) 0.81 (0.73-0.89)*** 1.27 (1.06-1.53)* 
‘Are dangerous’ 1.06 (1.01-1.11)* 1.27 (1.16-1.38)*** 0.75 (0.69-0.82)*** 1.15 (0.96-1.38) 
‘Never recover’ 0.94 (0.89-0.99)* 0.87 (0.79-0.95)*** 0.49 (0.44-0.56)*** 0.56 (0.46-0.69)*** 
‘Have selves to blame’ 0.94 (0.90-1.00)* 0.79 (0.71-0.87)*** 0.55 (0.49-0.61)*** 0.81 (0.66-1.01). 
*** p <0.001, ** p <0.01, * p < 0.05, . p < 0.1 
UOR = Unadjusted odds ratio; AOR = Adjusted odds ratio, CI=confidence interval 
 
